期刊
EXPERT OPINION ON ORPHAN DRUGS
卷 7, 期 1, 页码 1-10出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/21678707.2019.1552853
关键词
Leishmaniasis; drug resistance; amphotericin B
资金
- National Institute of Allergy and Infectious Diseases, NIH, USA [U19 AI074321]
Introduction: Leishmaniasis is one of the most neglected tropical infectious diseases in the world. Emergence of drug resistance and toxicity and high cost of the available drugs with lack of new antileishmanial drugs highlight the need to search for newer molecules with antileishmanial activities. Areas covered: This article describes the currently available antileishmanial drugs and their risk of developing resistance and discusses newer therapies. These include oral lipid-based formulations of amphotericin B, use of different drug delivery systems, and quinolone derivatives - naphthoquinone, buparvaquone, etc. Expert opinion: There are only a handful of antileishmanial drugs, and even fewer in the pipeline. Guideline-based treatment, with proper selection of antileishmanial compound, should be practiced. Combination therapy should be used preferably to prevent or delay drug resistance. As most patients with PKDL (post-kala-azar dermal leishmaniasis) are asymptomatic, it is important that shorter regimens are developed, which will encourage patients to opt for complete treatment. Pharmaceutical industry and not for profit' organizations should be encouraged to enhance the efforts in finding clinically effective antileishmanial drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据